1Schuler M, Rochlitz C, Horowitz JA, et al. A phase Ⅰ study of adenovirus-mediated p53 gene transfer in patients with advanced non-small cell lung cancer [J] . Hum Gene Ther, 1998, 9( 14):2075 - 2082.
2Dorigo O, Turla ST, Lebedeva S, et al. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function [J] . J Neurosurg, 1998, 88(3): 535 -540.
3Inoue A, Narumi K, Matsubara N, et al. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drug in human lung cancer cells irrespective of the status of p53 gene [J]. Cancer Lett, 2000, 157(1): 105-112.
4Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer [J]. J Clin Oncol, 2000, 18(3):609 - 622.
5Miyake H, Hara I, Hara S, et al. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirusmediated p53 gene transfer in human bladder cancer model [J].Urology, 2000, 56(2): 332 - 336.
6Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce Gl cell cycle arrest in response to DNA damage [ J ]. Cell, 2000, 102 ( 1 ): 55 - 66.
7Brown JM. NCI's anticancer drug screening program may not be selecting for clinically active compounds [J]. Oncol Res, 1997, 9(5):213 -215.
2Siddik ZH. Cisplatin mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22:7265-7279.
3Maeda T, Hobbs RM, Pandolfi PP. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res, 2005,65:8575-8578.
4Maeda T, Hobbs RM, Merghoub T, et al. Role of the proto- oncogene Pokemon in cellular transformation and ARF repression. Nature, 2005, 433:278-285.
5Gibson SL, Dai CY, Lee HW, et al. Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res, 2003, 63:742-746.
6Andrews GA, Xi S, Pomerantz RG, et al. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck, 2004, 26:870-877.
